Loading…
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $184M | $-19M | $-7M | $45M | -2.0% | 404.5% | - |
| 2024 | $37M | $-99M | $-89M | $-87M | -38.9% | 316.3% | - |
| 2023 | $9M | $-112M | $-105M | $-83M | -65.6% | -29.2% | - |
| 2022 | $12M | $-103M | $-101M | $-36M | -54.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 12.40 | 8.78 | 36.55 | 184.42 |
| Operating Expense | 116.76 | 123.55 | 137.93 | 205.01 |
| Operating Income | -104.36 | -114.77 | -101.37 | -20.59 |
| EBITDA | -102.81 | -112.30 | -99.19 | -18.82 |
| EBIT | -104.36 | -114.77 | -101.37 | -20.59 |
| Pretax Income | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income Common Stockholders | -101.07 | -104.70 | -88.98 | -6.88 |
| Total Expenses | 116.76 | 123.55 | 137.93 | 205.01 |
| Interest Income | 0 | 0 | 0 | 0 |
| Research And Development | 77.84 | 82.23 | 89.13 | 137.92 |
| Selling General And Administration | 38.92 | 41.32 | 48.79 | 67.09 |
| Normalized EBITDA | -102.81 | -112.30 | -99.19 | -18.82 |
| Normalized Income | -101.07 | -104.70 | -88.98 | -6.88 |
| Basic EPS | -2.60 | -2.38 | -1.65 | 0 |
| Diluted EPS | -2.60 | -2.38 | -1.65 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -101.07 | -104.70 | -88.98 | -6.88 |
| Reconciled Depreciation | 1.55 | 2.47 | 2.18 | 1.77 |
| Net Interest Income | 3.12 | 9.91 | 12.64 | 13.76 |
| Net Income From Continuing And Discontinued Operation | -101.07 | -104.70 | -88.98 | -6.88 |
| Total Operating Income As Reported | -104.36 | -114.77 | -101.37 | -20.59 |
| Diluted Average Shares | 38.90 | 43.99 | 54.01 | 0 |
| Basic Average Shares | 38.90 | 43.99 | 54.01 | 0 |
| Diluted NI Availto Com Stockholders | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income Including Noncontrolling Interests | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income Continuous Operations | -101.07 | -104.70 | -88.98 | -6.88 |
| Other Income Expense | 0.17 | 0.17 | -0.25 | -0.05 |
| Other Non Operating Income Expenses | 0.17 | 0.17 | -0.25 | -0.05 |
| Net Non Operating Interest Income Expense | 3.12 | 9.91 | 12.64 | 13.76 |
| Total Other Finance Cost | -3.12 | -9.91 | -12.64 | -13.76 |
| Interest Income Non Operating | 0 | 0 | 0 | 0 |
| General And Administrative Expense | 38.92 | 41.32 | 48.79 | 67.09 |
| Other Gand A | 38.92 | 41.32 | 48.79 | 67.09 |
| Operating Revenue | 12.40 | 8.78 | 36.55 | 184.42 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Stoke Therapeutics, Inc.this co. | STOK | $1.9B | - | 5.42 | -2.0% | -86.99 |
| Tyra Biosciences, Inc. | TYRA | $2.0B | - | 7.00 | -46.3% | -11.87 |
| Ocular Therapeutix, Inc. | OCUL | $2.0B | - | 3.04 | -40.6% | -5.06 |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.0B | 7.38 | 3.48 | 49.4% | 12.59 |
| Trevi Therapeutics, Inc. | TRVI | $2.0B |
| - |
| 9.68 |
| -23.3% |
| -32.27 |
| Pediatrix Medical Group, Inc. | MD | $1.9B | 11.57 | 2.21 | 19.1% | 7.93 |
| Omnicell, Inc. | OMCL | $1.9B | 828.21 | 1.38 | 0.2% | 18.60 |
| GeneDx Holdings Corp. | WGS | $1.8B | - | 5.97 | -6.8% | 141.02 |
| Inhibrx Biosciences, Inc. | INBX | $1.8B | - | 227.77 | -1752.2% | -13.63 |
| Peer Median | - | 11.57 | 4.72 | -15.1% | 1.43 | |